Evidence map›Paper›PMID 28316139›Full record

ArticleJournal of cachexia, sarcopenia and muscle2017

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis.

Anne Tournadre, Bruno Pereira, Fréderic Dutheil, Charlotte Giraud, Daniel Courteix, Vincent Sapin, Thomas Frayssac, Sylvain Mathieu, Sandrine Malochet-Guinamand, Martin Soubrier

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04175886 (Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis), which is not on this map. Cited by 99 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 6 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04175886 completednot on this mapstarted 2020, after this paper: background citation

Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project

TypeobservationalSponsorUniversity Hospital, LilleRan2020 to 2023Enrolled10ConditionsRheumatoid ArthritisArmsTofacitinib
3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 6 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Pro-Inflammatory Dietary Patterns Are Associated With Dyslipidemia, Poor Body Composition, and Sleep Quality Among Healthcare Workers: A Cross-Sectional Study.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Anne TournadreRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Bruno PereiraBiostatistics Unit (DRCI), CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Fréderic DutheilDepartment of Preventive and Occupational Medicine, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Charlotte GiraudRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Daniel CourteixLaboratory of Metabolic Adaptations to Exercise in Physiological and Pathological Conditions EA3533, University Clermont Auvergne, CNRS LaPSCo, Physiological and Psychosocial Stress, 24 Avenue des Landais, 63171, Aubière, France.
Vincent SapinBiochemistry and Molecular Biology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Thomas FrayssacRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Sylvain MathieuRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Sandrine Malochet-GuinamandRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Martin SoubrierRheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France.
Centre Hospitalier Universitaire de Clermont-Ferrand · FRSociété Française de Rhumatologie · FRAustralian Catholic University · AUUniversité Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by increased mortality associated with cardiometabolic disorders including dyslipidaemia, insulin resistance, and cachectic obesity. Tumour necrosis factor inhibitors and interleukin 6 receptor blocker licensed for the treatment of RA decrease inflammation and could thus improve cardiovascular risk, but their effects on body composition and metabolic profile need to be clarified. We investigated the effects of tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, on body composition and metabolic profile in patients treated for RA.

methodsTwenty-one active RA patients treated with TCZ were included in a 1 year open follow-up study. Waist circumference, body mass index, blood pressure, lipid profile, fasting glucose, insulin, serum levels of adipokines and pancreatic/gastrointestinal hormones, and body composition (dual-energy X-ray absorptiometry) were measured at baseline and 6 and 12 months of treatment. At baseline, RA patients were compared with 21 non-RA controls matched for age, sex, body mass index, and metabolic syndrome.

resultsCompared with controls, body composition was altered in RA with a decrease in total and appendicular lean mass, whereas fat composition was not modified. Among RA patients, 28.6% had a skeletal muscle mass index below the cut-off point for sarcopaenia (4.8% of controls). After 1 year of treatment with TCZ, there was a significant weight gain without changes for fat mass. In contrast, an increase in lean mass was observed with a significant gain in appendicular lean mass and skeletal muscle mass index between 6 and 12 months. Distribution of the fat was modified with a decrease in trunk/peripheral fat ratio and an increase in subcutaneous adipose tissue. No changes for waist circumference, blood pressure, fasting glucose, and atherogenic index were observed.

conclusionsDespite weight gain during treatment with TCZ, no increase in fat but a modification in fat distribution was observed. In contrast, muscle gain suggests that blocking IL-6 might be efficient in treating sarcopaenia associated with RA.

Indexed as

Absorptiometry, PhotonAgedAntibodies, Monoclonal, HumanizedArthritis, RheumatoidBody CompositionBody Mass IndexCase-Control StudiesFemaleFollow-Up StudiesHumansInterleukin-6Interleukin-6 InhibitorsMaleMetabolic SyndromeMetabolomeMiddle AgedAntibodies, Monoclonal, HumanizedIL6 protein, humanInterleukin-6Interleukin-6 InhibitorstocilizumabCachexiaMetabolic changeRheumatoid arthritisSarcopaeniaTocilizumab

Identifiers

PMID28316139
PMCPMC5566648
OpenAlexW2597303623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.